Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Non-small Cell Lung Cancer · Histiocytic Neoplasm · Histiocytosis · BRAF Gene Mutation · BRAF V600E · BRAF V600 Mutation · BRAF Mutation-Related Tumors · BRAF · Metastatic Lung Non-Small Cell Carcinoma · Metastatic Lung Cancer · Recurrent Lung Cancer · Recurrent Lung Non-Small Cell Carcinoma · NSCLC · Solid Tumor · Solid Carcinoma · KRAS G12D · KRAS G12V · KRAS Mutation-Related Tumors · NRAS Gene Mutation · Thyroid Cancer · Thyroid Carcinoma · Colorectal Cancer · Colorectal Carcinoma · Recurrent Histiocytic and Dendritic Cell Neoplasm · Brain Metastases · Recurrent NSCLC · KRAS G13C · Acquired Resistance to KRAS G12C Inhibitor · KRAS G12A · KRAS G12F · KRAS G12R · KRAS G13D

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Banner Health- MD Anderson Cancer Center, Gilbert, Arizona, United States
Contact: Study coordinator (Brandi Luzania) · Brandi.Luzania@bannerhealth.com · 480-256-5488
Contact: Principal Investigator (Jiaxin Niu, MD)
The Angeles clinic - A cedars SINAI AFFILIATE, Los Angeles, California, United States
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of California, San Francisco (UCSF), San Francisco, California, United States
University of Colorado - Aurora Cancer Center, Aurora, Colorado, United States
Contact: Study coordinator (Halle Kuykendall) · halle.kuykendall@cuanschutz.edu · 720-848-0356
Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
Georgetown University Lombardi Cancer Center, Washington D.C., District of Columbia, United States
Study coordinator · Chul.Kim@gunet.georgetown.edu · 202-444-2223
Contact: Principal Investigator (Chul Kim, MD)
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Start Your Patient Journey to Cancer Care and Support) · 877-442-3324
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
Contact: Study coordinator (Julie Burns) · julie.burns@startmidwest.com · 616-954-5559
Contact: Study coordinator (Jade Blakeman) · jade.blakeman@startmidwest.com · 616-954-5551
Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota, United States
Contact: Study coordinator (Amit Kulkarni, MBBS) · kulkarni@umn.edu · 612-624-0123
Contact: Study coordinator (Sara Crane) · crane202@umn.edu
Washington University, St Louis, Missouri, United States
Contact: Study coordinator (Medical Oncology Clinical Call Center) · MedicalOncologyClinicalCallCenter@dom.wustl.edu · 314-747-1171
NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Michael Offin, MD)
Study coordinator · 646-608-3763
Duke University School of Medicine, Durham, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
Sarah Canon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
START San Antonio, San Antonio, Texas, United States
NEXT Virginia, Fairfax, Virginia, United States
Contact: Study coordinator (Blake Patterson) · bpatterson@nextoncology.com · 703-783-4505
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Contact: Study coordinator (Rebecca Wood) · rwood1@seattlecca.org · 206-606-6970
Center for Cancer and Organ Diseases - Rigshospitalet, Copenhagen, Denmark
Queen Mary Hospital, Hong Kong, Hong Kong
Kyoto University Hospital, Kyoto, Japan
National Cancer Center Hospital, Tokyo, Japan
Contact: Study coordinator (Takafumi Koyama) · +81-3-3542-2511
University College London Hospital, London, United Kingdom
Hammersmith Hospital, London, United Kingdom
The Christie NHS Foundation Trust, Manchester, United Kingdom

View source on ClinicalTrials.gov Contact study team (email)